Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

NCT02974621 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Cediranib
DRUG: Cediranib Maleate
DRUG: Olaparib

Sponsor

National Cancer Institute (NCI)